WallStSmart

Medtronic PLC (MDT)vsSera Prognostics Inc (SERA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 43807307% more annual revenue ($35.48B vs $81,000). MDT leads profitability with a 13.0% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

SERA

Avoid

27

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: -5.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for SERA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

SERA2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

SERA4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$70.82M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : SERA

The strongest argument for SERA centers on Price/Book, Debt/Equity.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : SERA

The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

SERA carries more volatility with a beta of 1.02 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (56/100 vs 27/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Sera Prognostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sera Prognostics Inc. is a pioneering healthcare company focused on advancing maternal-fetal health through innovative diagnostic solutions. Leveraging its proprietary biomarker platform, Sera developed the PreTRM test to assess the risk of preterm birth, enabling timely clinical interventions that can significantly improve pregnancy outcomes. With a strong emphasis on collaboration with healthcare providers, Sera is poised to lead the prenatal diagnostics market, enhancing both maternal health and overall societal well-being. The company's dedication to innovation not only aims to foster healthier pregnancies but also seeks to generate long-term value for its investors.

Visit Website →

Want to dig deeper into these stocks?